Page 43 - IMCJ19s1

31. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols
Acknowledgements after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy
We would like to thank the Institute for Functional Medicine (IFM) CEO, Amy R. individuals. Clin Cancer Res. 2003;9(9):3312-3319.
Mack, the IFM COVID-19 Task Force, members of the IFM staff, and consultants 32. Isomura T, Suzuki S, Origasa H, et al. Liver-related safety assessment of green tea extracts
in humans: a systematic review of randomized controlled trials [published correction
working with IFM for their contributions to this document. appears in Eur J Clin Nutr. 2016;70(11):1221-1229]. Eur J Clin Nutr. 2016;70(11):1340.
doi:10.1038/ejcn.2016.78
33. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extracts: a systematic review
References by the US Pharmacopeia. Drug Saf. 2008;31(6):469-484. doi:10.2165/00002018-200831060-
1. Hotchkiss RS, Opal SM. Activating immunity to fight a foe - a new path. N Engl J Med. 00003
2020;382(13):1270-1272. doi:10.1056/NEJMcibr1917242 34. Oketch-Rabah HA, Roe AL, Rider CV, et al. United States Pharmacopeia (USP)
2. Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and comprehensive review of the hepatotoxicity of green tea extracts. Toxicol Rep. 2020;7:386-
IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti- 402. doi:10.1016/j.toxrep.2020.02.008
inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1. doi:10.23812/CONTI-E 35. Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of green tea catechins.
3. Ding S, Xu S, Ma Y, Liu G, Jang H, Fang J. Modulatory mechanisms of the NLRP3 EFSA J. 2018;16(4):e05239. doi:10.2903/j.efsa.2018.5239
inflammasomes in diabetes. Biomolecules. 2019;9(12):E850. doi:10.3390/biom9120850 36. McCarty MF, DiNicolantonio JJ. Nutraceuticals have potential for boosting the type 1
4. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome interferon response to RNA viruses including influenza and coronavirus. Prog Cardiovasc
coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50. Dis. Published online February 12, 2020. doi:10.1016/j.pcad.2020.02.007
doi:10.3389/fmicb.2019.00050 37. Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A review on various uses
5. Tőzsér J, Benkő S. Natural compounds as regulators of NLRP3 inflammasome-mediated of N-acetyl cysteine. Cell J. 2017;19(1):11-17. doi:10.22074/cellj.2016.4872
IL-1β production. Mediators Inflamm. 2016;2016:5460302. doi:10.1155/2016/5460302 38. Bauer IE, Green C, Colpo GD, et al. A double-blind, randomized, placebo-controlled study
6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin
cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. Psychiatry. 2018;80(1):18m12200. doi:10.4088/JCP.18m12200
doi:10.1016/S0140-6736(20)30628-0 39. Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial
7. Adem S, Eyupoglu V, Sarfraz I, Rasul A, Ali M. Identification of potent COVID-19 main therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and
protease (Mpro) inhibitors from natural polyphenols: an in silico strategy unveils a hope placebo [published correction appears in BMC Med. 2019;17(1):35]. BMC Med.
against CORONA. Preprints. Published online March 23, 2020. doi:10.20944/ 2019;17(1):18. doi:10.1186/s12916-019-1257-1
preprints202003.0333.v1 40. Clark RSB, Empey PE, Bayır H, et al. Phase I randomized clinical trial of N-acetylcysteine
8. Dostal Z, Modriansky M. The effect of quercetin on microRNA expression: a critical in combination with an adjuvant probenecid for treatment of severe traumatic brain injury
review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163(2):95-106. in children. PLoS One. 2017;12(7):e0180280. doi:10.1371/journal.pone.0180280
doi:10.5507/bp.2019.030 41. Bhatti J, Nascimento B, Akhtar U, et al. Systematic review of human and animal studies
9. Wu W, Li R, Li X, et al. Quercetin as an antiviral agent inhibits influenza A virus (IAV) examining the efficacy and safety of N-acetylcysteine (NAC) and N-acetylcysteine amide
entry. Viruses. 2015;8(1):E6. doi:10.3390/v8010006 (NACA) in traumatic brain injury: impact on neurofunctional outcome and biomarkers of
10. Kinker B, Comstock AT, Sajjan US. Quercetin: a promising treatment for the common oxidative stress and inflammation. Front Neurol. 2018;8:744. doi:10.3389/fneur.2017.00744
cold. J Anc Dis Prev Rem. 2014;2:2:1000111. doi:10.4172/2329-8731.1000111 42. Brisdelli F, D’Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple
11. Somerville VS, Braakhuis AJ, Hopkins WG. Effect of flavonoids on upper respiratory tract chemopreventive properties. Curr Drug Metab. 2009;10(6):530-546.
infections and immune function: a systematic review and meta-analysis. Adv Nutr. doi:10.2174/138920009789375423
2016;7(3):488-497. doi:10.3945/an.115.010538 43. Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERS-CoV
12. Qiu X, Kroeker A, He S, et al. Prophylactic efficacy of quercetin 3-β-O-D-glucoside against infection by resveratrol. BMC Infect Dis. 2017;17(1):144. doi:10.1186/s12879-017-2253-8
Ebola virus infection. Antimicrob Agents Chemother. 2016;60(9):5182-5188. doi:10.1128/ 44. Palamara AT, Nencioni L, Aquilano K, et al. Inhibition of influenza A virus replication by
AAC.00307-16 resveratrol. J Infect Dis. 2005;191(10):1719-1729. doi:10.1086/429694
13. Wong G, He S, Siragam V, et al. Antiviral activity of quercetin-3-β-O-D-glucoside against 45. Euba B, López-López N, Rodríguez-Arce I, et al. Resveratrol therapeutics combines both
Zika virus infection. Virol Sin. 2017;32(6):545-547. doi:10.1007/s12250-017-4057-9 antimicrobial and immunomodulatory properties against respiratory infection by
14. Yi YS. Regulatory roles of flavonoids on inflammasome activation during inflammatory nontypeable Haemophilus influenzae. Sci Rep. 2017;7(1):12860. doi:10.1038/s41598-017-
responses. Mol Nutr Food Res. 2018;62(13):e1800147. doi:10.1002/mnfr.201800147 13034-7
15. Sun Y, Liu W, Zhang H, et al. Curcumin prevents osteoarthritis by inhibiting the activation 46. Mendes da Silva D, Gross LA, Neto EPG, Lessey BA, Savaris RF. The use of resveratrol as
of inflammasome NLRP3. J Interferon Cytokine Res. 2017;37(10):449-455. doi:10.1089/ an adjuvant treatment of pain in endometriosis: a randomized clinical trial. J Endocr Soc.
jir.2017.0069 2017;1(4):359-369. doi:10.1210/js.2017-00053
16. Andres S, Pevny S, Ziegenhagen R, et al. Safety aspects of the use of quercetin as a dietary 47. Zhu CW, Grossman H, Neugroschl J, et al. A randomized, double-blind, placebo-
supplement. Mol Nutr Food Res. 2018;62(1). doi:10.1002/mnfr.201700447 controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of
17. Ożarowski M, Mikołajczak PŁ, Kujawski R, et al. Pharmacological effect of quercetin in Alzheimer’s disease: a pilot study. Alzheimers Dement (N Y). 2018;4:609-616. doi:10.1016/j.
hypertension and its potential application in pregnancy-induced hypertension: review of in trci.2018.09.009
vitro, in vivo, and clinical studies. Evid Based Complement Alternat Med. 2018;2018:7421489. 48. Roberts VH, Pound LD, Thorn SR, et al. Beneficial and cautionary outcomes of resveratrol
doi:10.1155/2018/7421489 supplementation in pregnant nonhuman primates. FASEB J. 2014;28(6):2466-2477.
18. Khaerunnisa S, Kurniawan H, Awaluddin R, Suhartati S, Soetjipto S. Potential inhibitor of doi:10.1096/fj.13-245472
COVID-19 main protease (Mpro) from several medicinal plant compounds by molecular 49. Klink JC, Tewari AK, Masko EM, et al. Resveratrol worsens survival in SCID mice with
docking study. Preprints. Published online March 13, 2020. doi:10.20944/ prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on
preprints202003.0226.v1 oncogenic pathways. Prostate. 2013;73(7):754-762. doi:10.1002/pros.22619
19. Yin H, Guo Q, Li X, et al. Curcumin suppresses IL-1β secretion and prevents inflammation 50. Shaito A, Posadino AM, Younes N, et al. Potential adverse effects of resveratrol: a literature
through inhibition of the NLRP3 inflammasome. J Immunol. 2018;200(8):2835-2846. review. Int J Mol Sci. 2020;21(6):E2084. doi:10.3390/ijms21062084
doi:10.4049/jimmunol.1701495 51. Salehi B, Mishra AP, Nigam M, et al. Resveratrol: a double-edged sword in health
20. Gong Z, Zhao S, Zhou J, et al. Curcumin alleviates DSS-induced colitis via inhibiting benefits. Biomedicines. 2018;6(3):E91. doi:10.3390/biomedicines6030091
NLRP3 inflammsome activation and IL-1β production. Mol Immunol. 2018;104:11-19. 52. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of
doi:10.1016/j.molimm.2018.09.004 resveratrol. Ann N Y Acad Sci. 2011;1215:161-169. doi:10.1111/j.1749-6632.2010.05853.x
21. Zhao J, Wang J, Zhou M, Li M, Li M, Tan H. Curcumin attenuates murine lupus via 53. Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and
inhibiting NLRP3 inflammasome. Int Immunopharmacol. 2019;69:213-216. doi:10.1016/j. opportunities for improved predictions. Drug Metab Dispos. 2014;42(3):301-317.
intimp.2019.01.046 doi:10.1124/dmd.113.055236
22. Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: 54. Mawson AR. Role of fat-soluble vitamins A and D in the pathogenesis of influenza: a new
multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325-1348. perspective. 2013;2013:246737. Int Sch Res Notices. doi:10.5402/2013/246737
doi:10.1111/bph.13621 55. Martineau AR, Jolliffe DA, Greenberg L, et al. Vitamin D supplementation to prevent acute
23. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of respiratory infections: individual participant data meta-analysis. Health Technol Assess.
tumeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161-168. 2019;23(2):1-44. doi:10.3310/hta23020
doi:10.1089/107555303321223035 56. Zhou J, Du J, Huang L, Wang Y, Shi Y, Lin H. Preventive effects of vitamin D on seasonal
24. Ng QX, Koh SSH, Chan HW, Ho CYX. Clinical use of curcumin in depression: a meta- influenza A in infants: multicenter, randomized, open, controlled clinical trial. Pediatr
analysis. J Am Med Dir Assoc. 2017;18(6):503-508. doi:10.1016/j.jamda.2016.12.071 Infect Dis J. 2018;37(8):749-754. doi:10.1097/INF.0000000000001890
25. Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS. A meta-analysis of the 57. Tzilas V, Bouros E, Barbayianni I, et al. Vitamin D prevents experimental lung fibrosis and
clinical use of curcumin for irritable bowel syndrome (IBS). J Clin Med. 2018;7(10):E298. predicts survival in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther.
doi:10.3390/jcm7100298 2019;55:17-24. doi:10.1016/j.pupt.2019.01.003
26. Bahramsoltani R, Rahimi R, Farzaei MH. Pharmacokinetic interactions of curcuminoids 58. Ricca C, Aillon A, Viano M, Bergandi L, Aldieri E, Silvagno F. Vitamin D inhibits the
with conventional drugs: a review. J Ethnopharmacol. 2017;209:1-12. doi:10.1016/j. epithelial-mesenchymal transition by a negative feedback regulation of TGF-β activity. J
jep.2017.07.022 Steroid Biochem Mol Biol. 2019;187:97-105. doi:10.1016/j.jsbmb.2018.11.006
27. Xu J, Qiu JC, Ji X, et al. Potential pharmacokinetic herb-drug interactions: have we 59. Fischer KD, Agrawal DK. Vitamin D regulating TGF-β induced epithelial-mesenchymal
overlooked the importance of human carboxylesterases 1 and 2? Curr Drug Metab. transition [published correction appears in Respir Res. 2015;16:139]. Respir Res.
2019;20(2):130-137. doi:10.2174/1389200219666180330124050 2014;15:146. doi:10.1186/s12931-014-0146-6
28. Matsumoto K, Yamada H, Takuma N, Niino H, Sagesaka YM. Effects of green tea catechins 60. Schrumpf JA, Ninaber DK, van der Does AM, Hiemstra PS. TGF-β1 impairs vitamin
and theanine on preventing influenza infection among healthcare workers: a randomized D-induced and constitutive airway epithelial host defense mechanisms. J Innate Immun.
controlled trial. BMC Complement Altern Med. 2011;11:15. doi:10.1186/1472-6882-11-15 2020;12(1):74-89. doi:10.1159/000497415
29. Lee HE, Yang G, Park YB, et al. Epigallocatechin-3-gallate prevents acute gout by 61. Liu RM, Gaston Pravia KA. Oxidative stress and glutathione in TGF-beta-mediated
suppressing NLRP3 inflammasome activation and mitochondrial DNA synthesis. Molecules. fibrogenesis. Free Radic Biol Med. 2010;48(1):1-15. doi:10.1016/j.freeradbiomed.2009.09.026
2019;24(11):E2138. doi:10.3390/molecules24112138 62. Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D3 protects against diabetic retinopathy
30. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls by inhibiting high-glucose-induced activation of the ROS/TXNIP/NLRP3 inflammasome
than promises? Int J Mol Sci. 2011;12(9):5592-5603. doi:10.3390/ijms12095592 pathway. J Diabetes Res. 2018;2018:8193523. doi:10.1155/2018/8193523
Evans—Virus-Specific Nutraceutical and Botanical Agents Integrative Medicine • Vol. 19, No. S1 • Epub Ahead of Print 41